These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36588706)

  • 1. Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice.
    Li S; Zhuge A; Wang K; Xia J; Wang Q; Han S; Shen J; Li L
    Front Pharmacol; 2022; 13():1081553. PubMed ID: 36588706
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
    PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
    Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
    Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
    Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
    Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
    World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
    Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
    Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
    Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
    Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
    J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice.
    Zhuge A; Li S; Yuan Y; Han S; Xia J; Wang Q; Wang S; Lou P; Li B; Li L
    Redox Biol; 2023 Feb; 59():102582. PubMed ID: 36584600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.